Technical Perspectives on Analyst's Rating Changes

NBIX case study
01-24-2007



NBIX - Rating change from "sector outperform" to "sector perform." FDA rejected a drug application and the stock is showing a huge loss today.

The stock had been trending down before today's downgrade. Performing poorly. Backing away from resistance. No indications of a reversal. Today's drop in the stock has taken it well below support. No indications of a reversal. This is a complete investment disaster.